Ganetespib

Phase 3Small molecule

Ganetespib is a small molecule that works as a Heat Shock Protein HSP90 Inhibitor.[2] It is being investigated across 18 indications, with its most advanced program in Phase 3.[1]

Ganetespib is one of 494 small molecule programs targeting Prostate Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

493

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate AdenocarcinomaActive, not recruiting

Lung CancerActive, not recruiting

Esophageal CancerActive, not recruiting

Malignant Pleural MesotheliomaActive, not recruiting

Malignant Peripheral Nerve Sheath TumorActive, not recruiting

Triple-Negative Breast CancerActive, not recruiting

Rectum CancerActive, not recruiting

Myelodysplastic SyndromeActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Prostate AdenocarcinomaPhase 2

Active, not recruiting

Lung CancerPhase 1

Active, not recruiting

Esophageal CancerPhase 1

Active, not recruiting

Malignant Pleural MesotheliomaPhase 1

Active, not recruiting

Malignant Peripheral Nerve Sheath TumorPhase 1/Phase 2

Active, not recruiting

Triple-Negative Breast CancerPreclinical

Active, not recruiting

Rectum CancerPhase 1

Active, not recruiting

Myelodysplastic SyndromePhase 1/Phase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Showing 10 of 18 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Ganetespib

SSynta Pharmaceuticals Corp.

Phase 3

4 2

Tecentriq

Roche

Preclinical

36 3

Tykerb

GSK

Preclinical

80 4

Trodelvy

Gilead

Preclinical

37 5

Prolia

Amgen

Preclinical

14 6

MS Contin

Merck & Co.

Preclinical

2 7

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 8

Chantix

PPrism Pharmaceuticals

Preclinical

1 9

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 10

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 2Recruiting

Breast Cancer

NCT01042379

Clinical

Trials by Indication[1]

Breast Cancer4 trials

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

Completed·—·Phase 2·NCT01560416·50 enrolled

An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer

Completed·SSynta Pharmaceuticals Corp.·Phase 2·NCT01677455·51 enrolled

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Recruiting·QQuantumLeap Healthcare Collaborative·Phase 2·NCT01042379·5,000 enrolled

Show 1 more trial

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT02060253·9 enrolled

Ovarian Cancer2 trials

GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer

Terminated·MMedical University Innsbruck·Phase 1/2·NCT02012192·133 enrolled

European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer

Completed·UUniversitaire Ziekenhuizen KU Leuven·Phase 2·NCT03783949·122 enrolled

Non-Small Cell Lung Carcinoma1 trial

Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT02192541·5 enrolled

Malignant Pleural Mesothelioma1 trial

Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma

Completed·UUniversity College, London·Phase 1/2·NCT01590160·27 enrolled

Multiple Myeloma1 trial

A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma

Completed·EEmory University·Phase 1·NCT01485835·8 enrolled

10 more indications

Gastrointestinal Stromal Tumor1 trial

A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)

Completed·SSynta Pharmaceuticals Corp.·Phase 2·NCT01039519·27 enrolled

Esophageal Cancer1 trial

Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02389751·3 enrolled

Advanced NSCLC1 trial

A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC

Terminated·SSynta Pharmaceuticals Corp.·Phase 3·NCT01798485·696 enrolled

Triple-Negative Breast Cancer1 trial

A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer

Withdrawn·UUniversity of Chicago·N/A·NCT02637375

Primary Peritoneal Cancer1 trial

Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Terminated·FFox Chase Cancer Center·Phase 1/2·NCT01962948·12 enrolled

Doxorubicin1 trial

A Phase I/II Study of Ganetespib in Combination With Doxorubicin

Terminated·GGeorgetown University·Phase 1/2·NCT02261805·11 enrolled

Malignant Peripheral Nerve Sheath Tumor1 trial

SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)

Completed·SSarcoma Alliance for Research through Collaboration·Phase 1/2·NCT02008877·20 enrolled

Head and Neck Cancers1 trial

Ganetespib Window of Opportunity Study in Head and Neck Cancers

Terminated·EEmory University·Phase 1·NCT02334319·3 enrolled

Lung Cancer1 trial

A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)

Completed·SSynta Pharmaceuticals Corp.·Phase 2·NCT01562015·12 enrolled

Myelodysplastic Syndrome1 trial

A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.

Completed·—·Phase 1/2·NCT01236144·113 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for Ganetespib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ganetespib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ganetespib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Synta Pharmaceuticals Corp. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Heat Shock Protein HSP90 Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSynta Pharmaceuticals Corp.

Ganetespib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Breast Cancer4 trials

Ovarian Cancer2 trials

Non-Small Cell Lung Carcinoma1 trial

Malignant Pleural Mesothelioma1 trial

Multiple Myeloma1 trial

Gastrointestinal Stromal Tumor1 trial

Esophageal Cancer1 trial

Advanced NSCLC1 trial

Triple-Negative Breast Cancer1 trial

Primary Peritoneal Cancer1 trial

Doxorubicin1 trial

Malignant Peripheral Nerve Sheath Tumor1 trial

Head and Neck Cancers1 trial

Lung Cancer1 trial

Myelodysplastic Syndrome1 trial

References

Drug Info

Quick Facts

Related News